December 24, 2024 07:24 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Allu Arjun quizzed by police in Pushpa 2 stampede case | Wanted Indian drug smuggler killed in the US | Congress leader files complaint against Allu Arjun for 'insulting police' in Pushpa 2: The Rule | Ahead of Jaishankar's US visit, foreign secretary Vikram Misri meets top US diplomats | India refrains from commenting on extradition request for ousted Bengladeshi PM Sheikh Hasina | I don't blame Allu Arjun, ready to withdraw case: Pushpa 2 stampede victim's husband | Indian New Wave Cinema Architect Shyam Benegal dies at age 90 | Cylinder blast at a temple in Karnataka's Hubbali injures nine people | Kuwait PM personally sees off Modi at airport as Indian premier concludes two-day trip | Three pro-Khalistani terrorists, who attacked a police outpost in Gurdaspur, killed in an encounter

Strides annonces that it commenced export of Favipiravir Antiviral Tablets developed by it

| @indiablooms | May 01, 2020, at 02:55 pm

Kolkata/IBNS: Strides Pharma Science Limited (Strides), a global pharmaceutical company, has announced that it has developed and commercialized Favipiravir Antiviral tablets.

The product is a generic version of Avigan® of Toyama Chemical, Japan, the company said in a release.

It said Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan.

In February 2020, post the outbreak of Novel Coronavirus(Covid-19), Favipiravir was studied in China and several other countries as an experimental treatment of Covid-19.

The drug has demonstrated positive outcomes,including a reduction in the duration of Covid-19 and improved lung conditions for the patients, according to the company.

Strides said it has developed Favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration and the product is currently being exported to GCC countries to treat patients under their treatment program for Covid-19.

Strides said it will also immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available in India.

Favipiravir tablets are being manufactured at Strides’ flagship facility in Bangalore, India.

Strides said it has also entered into a preferred arrangement with a leading Indian API manufacturer for the supplies of Favipiravir API.

The partner has already commercialized the Favipiravir API from its USFDA, KFDA, PMDA and WHO approved manufacturing facility and has capabilities to manufacture the Favipiravir API from its Key Starting Material (KSM) in-house, Strides said in its release.

Dr R Ananthanarayanan, CEO and Managing Director of Strides, said, “We are the first Indian company to develop and commercially launch Favipiravir tablets for the global markets. Favipiravir has already demonstrated positive outcomes in several studies on Covid-19 patients, and we are hopeful that the treatment regime with Favipiravir would brace up our fight against this virus."

Strides is a leading Indian supplier of drugs in the anti-retroviral,  anti-malarial, hepatitis and other infectious disease drug segments.

Image Credit: Strides-Facebook

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.